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Abstract
Background: Even after the Women’s Health Initiative (WHI) found that the risks of menopausal hormone therapy (hormone
therapy) outweighed benefit for asymptomatic women, about half of gynecologists in the United States continued to
believe that hormones benefited women’s health. The pharmaceutical industry has supported publication of articles in
medical journals for marketing purposes. It is unknown whether author relationships with industry affect promotional tone
in articles on hormone therapy. The goal of this study was to determine whether promotional tone could be identified in
narrative review articles regarding menopausal hormone therapy and whether articles identified as promotional were more
likely to have been authored by those with conflicts of interest with manufacturers of menopausal hormone therapy.
Methods and Findings: We analyzed tone in opinion pieces on hormone therapy published in the four years after the
estrogen-progestin arm of the WHI was stopped. First, we identified the ten authors with four or more MEDLINE-indexed
reviews, editorials, comments, or letters on hormone replacement therapy or menopausal hormone therapy published
between July 2002 and June 2006. Next, we conducted an additional search using the names of these authors to identify
other relevant articles. Finally, after author names and affiliations were removed, 50 articles were evaluated by three readers
for scientific accuracy and for tone. Scientific accuracy was assessed based on whether or not the findings of the WHI were
accurately reported using two criteria: (1) Acknowledgment or lack of denial of the risk of breast cancer diagnosis associated
with hormone therapy, and (2) acknowledgment that hormone therapy did not benefit cardiovascular disease endpoints.
Determination of promotional tone was based on the assessment by each reader of whether the article appeared to
promote hormone therapy. Analysis of inter-rater consistency found moderate agreement for scientific accuracy (k=0.57)
and substantial agreement for promotional tone (k=0.65). After discussion, readers found 86% of the articles to be
scientifically accurate and 64% to be promotional in tone. Themes that were common in articles considered promotional
included attacks on the methodology of the WHI, arguments that clinical trial results should not guide treatment for
individuals, and arguments that observational studies are as good as or better than randomized clinical trials for guiding
clinical decisions. The promotional articles we identified also implied that the risks associated with hormone therapy have
been exaggerated and that the benefits of hormone therapy have been or will be proven. Of the ten authors studied, eight
were found to have declared payment for speaking or consulting on behalf of menopausal hormone manufacturers or for
research support (seven of these eight were speakers or consultants). Thirty of 32 articles (90%) evaluated as promoting
hormone therapy were authored by those with potential financial conflicts of interest, compared to 11 of 18 articles (61%)
by those without such conflicts (p=0.0025). Articles promoting the use of menopausal hormone therapy were 2.41 times
(95% confidence interval 1.49–4.93) as likely to have been authored by authors with conflicts of interest as by authors
without conflicts of interest. In articles from three authors with conflicts of interest some of the same text was repeated
word-for-word in different articles.
Conclusion: There may be a connection between receiving industry funding for speaking, consulting, or research and the
publication of promotional opinion pieces on menopausal hormone therapy.
Please see later in the article for the Editors’ Summary.
PLoS Medicine | www.plosmedicine.org 1 March 2011 | Volume 8 | Issue 3 | e1000425Citation: Fugh-Berman A, McDonald CP, Bell AM, Bethards EC, Scialli AR (2011) Promotional Tone in Reviews of Menopausal Hormone Therapy After the
Women’s Health Initiative: An Analysis of Published Articles. PLoS Med 8(3): e1000425. doi:10.1371/journal.pmed.1000425
Academic Editor: Joel Lexchin, York University, Canada
Received September 14, 2009; Accepted February 3, 2011; Published March 15, 2011
Copyright:  2011 Fugh-Berman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study received no external or internal funding, and none of the authors received any funds or salary support for conducting this study.
Competing Interests: Adriane Fugh-Berman directs PharmedOut (http://www.pharmedout.org/), a Georgetown University Medical Center project that
educates physicians about inappropriate pharmaceutical marketing practices. Dr. Fugh-Berman is also a paid expert witness on behalf of women who developed
breast cancer while taking menopausal hormone therapy. Alicia M. Bell was the paid project manager of PharmedOut during part of the time this study was
conducted. Christina McDonald and Emily Catherine Bethards received graduate school credit for their work on this study while they were master’s students in
Physiology at Georgetown University Medical Center.
Abbreviations: CI, confidence interval; WHI, Women’s Health Initiative
* E-mail: Ajf29@georgetown.edu
" CPM, ECB, and AMB are currently medical students at, respectively, Georgetown University School of Medicine, Penn State University School of Medicine, and
Virginia Commonwealth University.
Perfect Pitch
PLoS Medicine | www.plosmedicine.org 2 March 2011 | Volume 8 | Issue 3 | e1000425Introduction
About half of US gynecologists continue to distrust the results of
the Women’s Health Initiative (WHI) [1,2,3], which found that
risks of menopausal hormone therapy outweighed benefits in
asymptomatic women. Such resistance to the findings of the largest
randomized, placebo-controlled trial of menopausal hormone
therapy ever performed is curious.
The WHI enrolled more than 26,000 women. After more than
five years of follow-up, the estrogen-progestin arm of the WHI was
stopped in 2002 due to harm; the estrogen-only arm was stopped
in 2004, also due to harm [4,5]. Both therapies increased the risk
of stroke, deep vein thrombosis [4,5], dementia [6], and
incontinence [7]; estrogen-progestin therapy also increased rates
of breast cancer [4]. Neither therapy reduced cardiovascular risk,
and neither markedly benefited health-related quality of life
measures [8,9].
Over the year after the first WHI results were announced,
hormone prescriptions dropped by 80% [10]. Compared to 2002,
the age-adjusted incidence of breast cancer diagnosis dropped
6.7% in 2003, a finding attributed to decreased use of hormone
therapy among postmenopausal women [11,12]. A recent report
confirmed an increased breast cancer incidence and a doubling of
breast cancer-associated deaths among hormone users in the WHI
[13].
In the US, gynecologists were more likely than internists or
family physicians to prescribe hormone therapy to asymptomatic
women both before [14,15] and after [16,17] the WHI. Between
1999 and 2002, 90 million hormone therapy prescriptions were
written annually [18]. In 2002, US gynecologists wrote 70% of
estrogen or estrogen-progestin prescriptions [19]. Sixteen months
after the WHI ended, a survey of 705 fellows of the American
College of Obstetricians and Gynecologists found that 49.1% of
gynecologists did not find the WHI convincing and that 48.1%
disagreed with the decision to stop the trial [1]. Follow-up surveys
found similar results [2,3].
Publications in the medical literature by industry-paid physi-
cians have recently received attention [20]. Several academic
analyses have used internal industry documents disclosed in
litigation to document the use of messaging in publications
regarding rofecoxib (Vioxx) [21], gabapentin (Neurontin) [22],
and sertraline (Zoloft) [23]. Thousands of internal documents are
available at the Drug Industry Document Archive (http://dida.
library.ucsf.edu/). Industry-funded reviews and commentaries
may be designed to convey specific, but subtle, marketing
messages [24]. As a possible explanation for why so many physi-
cians continue to support the use of menopausal hormone therapy
in asymptomatic women, we investigated whether promo-
tional tone could be identified in narrative review articles
regarding menopausal hormone therapy and whether articles
identified as promotional were more likely to have been authored
by those with conflicts of interest as determined by declared
payments from hormone manufacturers.
Methods
Search Strategy
In 2006, we conducted a MEDLINE search using Ovid, limited
to English language reviews or comments published from July
2002 through June 2006 (the four years after cessation of the
estrogen-progestin arm of the WHI). The search terms were
‘‘estrogen replacement therapy’’ combined with ‘‘breast neoplasms
AND menopause’’ or ‘‘cardiovascular disease AND menopause’’;
‘‘hormone replacement therapy’’ combined with ‘‘breast neo-
plasms AND menopause’’ or ‘‘cardiovascular disease AND
menopause’’; and ‘‘menopausal hormone therapy’’ combined
with ‘‘breast cancer.’’ A list of all authors was made and the
number of publications per author assessed. A subset of the most
prolific authors was identified. One reader (CPM) assessed article
titles, eliminating articles that did not focus on benefits and risks of
combined estrogen-progestin menopausal hormone therapy since
the WHI. An additional MEDLINE search was conducted using
the names of these authors to identify other relevant articles.
Analysis of Content
Articles were obtained, and information on identifying authors
and affiliations was removed, by support staff. All articles were
independently evaluated for scientific accuracy and for tone by
three readers (CPM, ECB, AMB) who were then graduate
students in physiology. We used graduate students in physiology
as readers because these individuals have the requisite knowledge
to understand the technical aspects of the literature but have no
experience as health care providers or as the targets of pharm-
aceutical promotional efforts. Scientific accuracy was assessed
based on whether or not the findings of the WHI were accurately
reported using two criteria:
1. Acknowledgment or lack of denial of the risk of breast cancer
diagnosis associated with menopausal hormone therapy, and
2. Acknowledgment that menopausal hormone therapy did not
benefit cardiovascular disease endpoints.
Determination of tone was based on each reader’s assessment of
whether the article appeared to promote hormone therapy (such
articles were deemed ‘‘promotional’’) or not (articles deemed
‘‘nonpromotional’’ were either neutral about hormone therapy or
argued against routine use). Because no validated tools exist for
assessing tone, each reader made her determination according to
personal criteria. Readers were asked to record features of each
article supporting their assessments. Assessments were discussed
only at team meetings, and readers did not otherwise communi-
cate with each other about the articles.
The initial literature search identified 340 articles with a total of
428 authors. Ten authors had published four, five, or six articles;
47 authored two or three articles; and 371 authored one article
each. We then excluded articles that focused on selective estrogen
receptor modulators, androgens, specific receptors, or specific
mechanisms, and other articles unlikely to discuss the risks and
benefits of menopausal hormone therapy. After excluding these
articles, 232 potentially relevant articles remained.
The ten authors who had published four to six articles
accounted for 47 (20%) of these articles. We chose to focus on
these ten authors because they contributed a fifth of the extant
literature during the four-year period under study, and could be
assumed to have been widely read and thus influential. An
additional literature search using these author names identified 13
additional relevant articles for a total of 60 articles for blinded
evaluation by the three readers. Ten articles were subsequently
excluded by mutual agreement of all readers (two publications
were letters, three were duplicated references, four covered topics
outside the scope of the study and did not specifically address our
criteria, and one was published before July 2002). The remaining
50 papers, listed in Text S1, were evaluated individually by all
readers. The ten authors who published four or more articles in
the four-year period under study are identified in Table 1.
After individually analyzing a batch of articles, readers met to
provide their initial assessments, to discuss them, and to come to
consensus, if possible, on scientific accuracy and tone. Disagree-
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majority vote. After all articles had been evaluated individually
and together by all readers, the authors were revealed and a search
was performed for potential financial conflicts of interest, defined
as evidence that the authors had received payment for research,
speaking, or consulting on behalf of a manufacturer of menopausal
hormone therapy.
Assessment of Conflicts of Interest
Conflicts of interest were assessed by examining published
declarations within MEDLINE-indexed articles, disclosures from the
Council on Hormone Education (a Wyeth-funded group of con-
sultants) [25–28], and a Google search of each author’s name
combined with the term ‘‘conflict of interest.’’ Conflicts of interest were
assessed for the time period ending 30 June 2006. No evaluations of
potential conflicts of interest disclosed after that date were attempted.
Statistical Analysis
The Fisher exact test was used to assess the distribution of
articles between conflicted and nonconflicted authors. A two-sided
p-value of 0.05 or less was accepted as statistically significant. Risk
ratios were estimated using the SABER program from the US
Centers for Disease Control and Prevention. The kappa statistic
(k) was calculated according to the method of Brennan and
Prediger [29].
Results
The majority of articles (86%) were judged to be scientifically
accurate according to our analysis. Thirty-two (64%) of the 50
articles were assessed as promotional.
After individual evaluation, all three readers agreed on both
scientific accuracy and tone for half (50%) of the articles. Readers
wereinagreementregardingscientificaccuracyfor34articles(68%)
and regarding promotional tone for 39 articles (78%). Analysis of
inter-rater consistency found moderate agreement for scientific
accuracy (k=0.57) and substantial agreement for promotional tone
(k=0.65). After the consensus discussions, there was agreement
regarding scientific accuracy for 49 articles (98%) and regarding
promotional tone for 48 (96%) articles. Overall, readers were in
94% agreement prior to unmasking the identity of the authors.
Themes in Promotional Articles
Readers identified themes common among promotional articles.
These themes included:
N The WHI was flawed.
N The WHI was a controversial trial.
N The population studied in the WHI was inappropriate or was
not representative of the general population of menopausal
women.
N Clinical trial results should not guide treatment for individuals.
N Observational studies are as good as or better than
randomized clinical trials.
N Animal studies can guide clinical decision-making.
N The risks associated with hormone therapy have been
exaggerated.
N The benefits of hormone therapy have been or will be proven;
recent studies are an aberration.
For examples of statements representative of the themes identified,
see Table 2. Examples of what were considered promotional and
nonpromotional treatments of similar topics are given in Table 3.
Articles evaluated as promotional frequently differed from
nonpromotional articles in the way that risks were presented. For
example, most articles conceded that hormone therapy was
associated with breast cancer, but promotional articles contained
statements such as ‘‘The risk of breast cancer with hormonal therapy
is put into perspective with the realization that this risk is related to
hormonal dose and duration of use, and that the absolute riskremains
small’’ (reference A14 in Text S1), or ‘‘The WHI agreed with
convincing evidence in the literature that postmenopausal hormone
therapy does not increase the risk of breast cancer beyond that
already associated with recognized risk factors, such as a positive
family history’’ (A10 in Text S1). A nonpromotional article stated
‘‘Although estrogen and/or progestin effectively reduce vasomotor
symptoms, a recent WHI randomized trial identified an unfavorable
risk/benefit balance on life-threatening diseases, including increased
breast cancer, for combined estrogen plus progestin use in otherwise
healthy post-menopausal women’’ (A40 in Text S1). See Table 3 for
more examples of statements that minimize risks.
Reuse of Previously Published Text
Our analysis also found, incidentally, that three authors we
identified as having financial conflicts of interest were authors on
articles where sections of their previously published articles were
repeated word-for-word. Neither of the authors without declared
conflicts of interest were noted to have reused text in the articles
analyzed.
Eighty-four percent of the text and all seven tables in one article
(A9 in Text S1) were found in four other articles by Leon Speroff
(A8, A10, A30, and A50 in Text S1). Seventy-three percent of the
text and seven of ten tables from one of these articles (A10 in Text
S1) were found in three other articles by this author (A9, A30, and
A50 in Text S1). More than half (55%) of the text of one article
(A8 in Text S1), published in Maturitas, was reused in the same
Table 1. Scientific accuracy and promotional tone in articles
on menopausal hormone therapy.
Articles authored
or coauthored
by authors with
potential financial
conflicts of interest
a
(41 total)
Articles authored
or coauthored
by authors without
potential financial
conflicts of interest
b
(9 total)
Scientific
accuracy
No 6
c 1
d
Yes 35
e 8
f
Promotional
tone
No 11
g 7
h
Yes 30
i 2
j
aAuthors with potential financial conflicts of interest: Leon Speroff, Thomas B.
Clarkson, Peter Kenemans, Rogerio A. Lobo, David M. Herrington, Marius J. van
der Mooren, Rowan T. Chlebowski, Susan R. Davis.
bAuthors with no evidence of potential financial conflicts of interest: Nanette K.
Wenger, Nananda F. Col.
The following footnotes indicate references listed in Text S1.
cA10, A12, A25, A29, A35, A45.
dA4.
eA1-2, A5, A8-9, A11, A14, A15-24, A26-27, A30-34, A36-38, A40-43, A46-48, A50.
fA3, A6-7, A13, A28, A39, A44, A49.
gA1-2, A16-17, A22, A24-25, A32, A46, A47-48.
hA6-7, A13, A28, A39, A44, A49.
iA5, A8, A9-12, A14-15, A18-21, A23, A26-27, A29-31, A33-38, A40-43, A45, A50.
jA3, A4.
doi:10.1371/journal.pmed.1000425.t001
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publication was made.
Twenty-five percent of an article coauthored by Susan R. Davis
was reused (A25 in Text S1) in another article coauthored by the
same author, without acknowledgment of earlier publication (A26
in Text S1). Both articles included additional authors and we could
not determine which authors were responsible for the reuse. Over
two-thirds (71%) of the text of an article by Rogerio A. Lobo (A33
in Text S1), as well as its two figures and table, were reused (A14 in
Text S1); in this case, adaptation, but not republication, was
acknowledged (A14 in Text S1).
Conflicts of Interest
Of the ten authors in our sample, eight were found to have
received payment for research, speaking, or consulting on behalf of
menopause hormone manufacturers (Table 1). About half of the
articles analyzed had coauthors in addition to the ten authors we
assessed, but we did not examine whether there were potential
financial conflicts of interest for these coauthors.
The assessments of scientific accuracy and promotional tone after
the consensus discussion are summarized in Table 1 according to
author’s potential conflict of interest. Thirty of 32 articles (90%)
evaluated as promoting hormone therapy were authored by those
with conflicts of interest compared to 11 of 18 articles (61%) by those
without conflicts of interest. The difference was significant (p=
0.0025). Two of nine articles (22%) by authors without known
conflictswereconsidered promotional,and30of41articles(73%)by
authors with known conflicts were considered promotional. Articles
promoting the use of menopausal hormone therapy were 2.41 times
(95% CI1.49–4.93) morelikely to have been written byauthors with
conflicts of interest than by authors without conflicts of interest.
Discussion
This study evaluated the relationship between the receipt by
authors of payment from industry for speaking or consulting and
authorship of articles considered to be scientifically in error or
promotional in tone. We identified an association of review articles
promoting the use of hormone therapy with authors with declared
Table 2. Themes consistently identified in promotional articles, with examples.
Theme Examples
a
The Women’s Health
Initiative was flawed.
‘‘Will postmenopausal hormone therapy begun at or near the time of the menopause, and maintained for a relatively
long duration of time, provide protection against coronary artery disease (primary prevention)? The design of the
canceled arm of the WHI did not allow an answer to this question.’’ (A10, A50)
The Women’s Health Initiative
was a controversial trial.
‘‘The proper role of hormone replacement therapy (HRT) for the treatment and prevention of cardiovascular disease
remains a controversial and heavily debated topic.’’ (A32)
‘‘… we cannot formulate any general advice that holds for the majority of European post-menopausal women due to
lack of consistency, lack of biological plausibility, and lack of relevance of randomized clinical trial data to our daily
practical work.’’ (A11)
‘‘Therefore, the WHI results are questionable and uncertain even if obtained in a gold standard randomized clinical
trial, and for sure these data cannot be extrapolated to the younger and healthier perimenopausal women.’’ (A35)
The population studied in the Women’s
Health Initiative was inappropriate or was
not representative of the general
population of menopausal women.
‘‘In the three large RCTs available, the populations studied are: not representative, too old and without climacteric
complaints, and therefore lacking any indication for postmenopausal hormone therapy (HT).’’ (A11)
‘‘Randomized controlled trials are very powerful investigative tools that are, by design, limited in their interpretation
to populations covered by the randomized controlled trial.’’ (A43)
Clinical trial results should not guide
treatment for individuals.
‘‘To do as the editorialists recommend (to categorically discourage the use of hormone therapy) is to deny women
the assistance they need to make individual decisions based upon individual characteristics and needs.’’ (A8)
Observational studies are as good or
better than randomized clinical trials.
‘‘However, a truly randomized, placebo-controlled, HT trial in women entering menopause is very difficult or even
impossible to carry out in practice and observational studies are more akin to the approach of physicians in clinical
practice.’’ (A31)
Animal studies can guide
clinical decision-making.
‘‘There is strong evidence that ET/HT provides cardioprotection in primary prevention studies of animal models with
supportive data from studies of women in the EPAT and Nurses’ Health Study.’’ (A27)
The risks associated with hormone
therapy have been exaggerated.
‘‘The important unanswered question is whether hormone therapy causes breast cancer or is promoting the
diagnosis of pre-existing tumors.’’ (A8)
‘‘It is also worth pointing out that the reported risk with hormone therapy is even smaller than that associated with
recognized risk factors such as a positive family history, being overweight after menopause, and alcohol intake.’’
(A10, A30, A50)
‘‘However, this proportion was not due to an epidemic of breast cancer in the HRT group but rather to an
unexplained decreased incidence of breast cancer cases in the placebo group.’’ [35]
‘‘It is helpful to emphasize the possibility that the studies reflect an effect of hormone therapy on preexisting
tumors[,] and that hormone users who develop breast cancer have a reduced risk of dying of breast cancer because
their tumors are better differentiated, more localized, and smaller.’’ (A10, A30, A50)
The benefits of hormone therapy have
been or will be proven; recent studies
are an aberration.
‘‘Mortality from all causes is lower in HRT users compared with non-users.’’ (A12)
‘‘However, even after the most contemporary and careful attempts to adjust for possible confounders, HRT use
continues to be associated with more favorable outcomes.’’ (A15)
‘‘With many observational trials indicating a cardioprotective effect of early estrogen treatment and the absence of a
prospective, randomized clinical trial powered to reveal cardioprotection starting during the menopausal transition it
seems prudent not to dismiss such an effect.’’ (A43)
‘‘There continues to be good reason to believe that there are benefits associated with treatment, including
improvement of quality of life beyond the relief of hot flushes, maximal protection against osteoporotic fractures, a
reduction in colorectal cancers, maintenance of skin turgor and elasticity, and the possibility of primary prevention of
CHD and Alzheimer’s disease.’’ (A10)
aSee Text S1 for referenced articles given in parenthesis.
doi:10.1371/journal.pmed.1000425.t002
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be affected by author conflicts of interest.
The effect of industry funding on results in clinical trials [30],
meta-analyses [31,32], clinical practice guidelines [33], and pay-
for-performance quality measures [34] has been well documented.
Two publications have documented scientifically unsupportable
statements on the risks and benefits of menopausal hormone
therapy in the medical literature [19,35]; many of these statements
appeared in reviews, commentaries, editorials, and letters.
We assessed scientific accuracy based on whether or not two
findings of the WHI were accurately reported: (1) There is no
proven cardioprotective effect of estrogen-progestin therapy in
menopausal women or in ten-year age subgroups of menopausal
women, and (2) breast cancer is diagnosed more frequently in
menopausal women receiving estrogen-progestin therapy [4,36].
Promotional tone was evaluated without formal criteria, but the
readers were asked to identify elements of the articles that
conveyed a promotional tone. Readers evaluated articles masked
as to the identity or affiliations of the authors. Prior to discussion,
there was substantial agreement among the individual readers for
promotional tone, and moderate agreement on scientific accuracy.
After discussion, but prior to unmasking of author identities, there
was consensus on both measures for all but two of the 50 papers
evaluated.
We found that articles with a promotional tone were more likely
to have been written by authors who had disclosed financial
conflicts of interest than by authors without such disclosures.
These conflicts were determined through publicly available
declarations of conflicts of interest and may not be accurate or
complete. It is possible, for example, that authors whom we
identified as having no potential conflicts had undeclared conflicts
or developed conflicts after the period we examined. One author,
Nanette Wenger, for whom we identified no potential conflicts
with hormone manufacturers during our study, later declared
potential conflicts [37].
Our sample size of ten authors was small, although the authors
assessed had written one out of five of the articles identified in our
search. The prevalence of financial conflicts among authors in
general is unknown, and our findings may not reflect the universe
of authors. It is possible that an assessment that included less
prolific authors would come to a different conclusion.
Almost all articles were evaluated as scientifically accurate
regarding the effect of hormones on breast cancer diagnosis and
cardiovascular risk, but readers found phrasing that minimized the
risk of breast cancer or seemed to encourage reliance upon animal
studies, observational studies, or expert recommendations rather
than on randomized controlled trials. Our results support an in-
depth interview study that found that physicians at two health
plans commonly believed that WHI ‘‘was not applicable to the full
range of patients seen in clinical practice’’ and ‘‘created
uncertainty about the risks and benefits of HT’’ [38].
Our results suggest that authors who have received payments
from industry convey more enthusiasm about the industry’s
products than do authors who have not declared that they received
such payments. These results support the findings of a study that
examined conflicts of interest in reviews (among other publica-
tions) and found that articles by authors with potential financial
conflicts of interest were more likely to support the use of a specific
class of drug therapy [39]. The question of whether positive
feelings about hormone therapy preceded payments from industry
and were perhaps a basis for selection of these physicians as
speakers and consultants or whether selection as a speaker or
consultant led to more positive feelings about hormone therapy is
an issue that should be explored in further research.
Our findings also support an analysis by Tatsioni and colleagues
of ‘‘partisan editorializing articles on HRT’’ in the Thomson ISI
database by five editorialists who had written at least 12 commen-
taries in medical journals between 2002 and 2008 [40]. All five
had financial relationships with hormone manufacturers; these
relationships were reported in only six of the 110 articles analyzed.
Table 3. Examples of language promoting or not promoting the use of hormone therapy.
Promotional Nonpromotional
‘‘…the WHI did not study the appropriate population
in the appropriate time period to establish that
hormone therapy does not exert a primary preventive
effect on the risk of CHD.’’ (A10, A50)
‘‘The role of conventional HRT for treatment and prevention
of CHD is rapidly evolving from presumed benefit to proven harm.’’ (A46)
‘‘Are such experts jumping to conclusions, and
jeopardizing the health and quality of life of
these peri- and early postmenopausal women,
who differ from those in the WHI trial, two-thirds
of whom were over 60 years old?’’ (A18)
‘‘…use of menopausal hormone therapy (MHT) for chronic
disease risk reduction in any population cannot be supported.’’ (A47)
‘‘Wherever we live we are surrounded by risks,
sometimes not known to us. Air and water pollution,
various forms of radiation, insecticides in food and
road accidents are good examples. Do we stop
using the car? Certainly not! We take the small
risk because of the benefits.’’ (A35)
‘‘Although the majority of WHI women had no adverse events, the population
risk is substantial, such that the global risk: benefit profile does not warrant
recommendation of this therapy as a widespread preventive intervention.’’ (A7)
‘‘Given the practical challenges in conducting
randomized controlled trials to compare the various
estrogens, drawing inferences from valid observational
studies seems the only realistic alternative.’’ (A3)
‘‘Observational studies have inherent biases that cannot be corrected for;
therefore evidence should come from randomized clinical trials (RCTs).’’ (A11)
‘‘The use of animal models allows for the evaluation
of direct breast cancer effects of ET [estrogen therapy]
and HT and avoids some of the confounding variables
that are necessarily a part of studies on
postmenopausal women.’’ (A38)
‘‘…observational or mechanistic studies, animal models, and basic
research have tremendous value for the generation of hypotheses
but should not be used to justify broad-based pharmacologic interventions.’’ (A5)
See Text S1 for referenced articles given in parenthesis.
doi:10.1371/journal.pmed.1000425.t003
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Tatsioni analysis and ours, Tatsioni and colleagues identified
similar themes, noting that common arguments included ‘‘HRT is
effective for menopausal and related symptoms’’; ‘‘Discussion of
preclinical data that showed favorable effects for HRT’’;
‘‘Statements challenging/criticizing unfavorable studies’’ (especial-
ly against the WHI and the Million Women Study); and
‘‘Statements that HRT may decrease life-threatening and other
serious outcomes.’’ Additionally, Tatsioni et al. note that text was
sometimes repeated verbatim in several articles; examples are
provided in their online supplemental materials [40].
A scientist who consults for the pharmaceutical industry has
described the process by which companies formulate key
marketing messages into a product narrative to affect the discourse
of medicine and ultimately medical knowledge [41]. Although
promotional linguistic and rhetorical strategies have been
identified in television commercials for prescription drugs [42],
there is a dearth of academic articles on the use of rhetoric and
persuasion in medical journal articles. To our knowledge, the
study by Tatsioni et al. and our study are the first to attempt to
assess tone in review articles published in medical journals.
The extent of text reuse we identified was surprising. Tatsioni
et al. documented different examples of text repeated verbatim
in articles on menopausal hormone therapy, raising the question
of how many more articles in the medical literature contain
previously published passages. An editorial in The Lancet noted
that text recycling in review material could be viewed as ‘‘less
of a crime’’ than ‘‘self-plagiarism’’ of original research, but that
the practice ‘‘constitutes intellectual laziness at best’’ and is
unacceptable [43].
Limitations
The methodology used to evaluate promotional tone for this
study has not been previously validated. Our evaluators were not
physicians and it is possible that the use of physician evaluators
would have yielded different results.
It is possible that the authors for whom no conflicts of interest
were found actually did have conflicts of interest, either because
we failed to identify a conflict or because a conflict was not
disclosed. Misclassification of conflicted authors would be expected
to bias the study results toward the null and is unlikely to be
responsible for the difference in tone that we identified.
We cannot be certain that the ten authors we evaluated were
representative of the universe of authors writing review articles on
hormone therapy during the study period. We selected these
authors because they were responsible for 20% of the relevant
literature during the time period, but a study of authors with fewer
publications during the period may have revealed different results.
We also did not assess possible conflicts of interest of coauthors or
the contribution these coauthors may have made to the accuracy
or tone of the articles we assessed.
The assessment of multiple articles by each author may introduce
an overcounting problem in the statistical analysis inasmuch as each
author’s perspective might be expected to stay the same. However,
as can be seen in Table 1, about a quarter of articles by authors with
potential financial conflicts of interest were deemed nonpromo-
tional, and about a quarter of articles by those without potential
financial conflicts of interest were deemed promotional.
Documents recently disclosed in litigation against manufactur-
ers of hormone therapy revealed that dozens of articles ghost-
written by industry were published in the medical literature
[44,45]. The names of two of the authors whose work we assessed,
Rogerio Lobo and Leon Speroff, were on the bylines of some of
the reportedly ghostwritten articles [45–55]. We could not
determine whether or not any of the articles assessed in our study
were ghostwritten.
Conclusion
Our study found that narrative review articles on hormone
therapy may provide accurate statements about the risks of a
therapy while simultaneously providing positive impressions of
that therapy for uses unsupported by evidence. There may be a
connection between industry funding for research, speaking,
or consulting and the publication of promotional pieces on
menopausal hormone therapy. Health care providers should
exercise caution if they choose to read such articles. We believe
that medical journals should follow the International Committee
of Medical Journal Editors Uniform Requirements for Manu-
scripts (http://www.icmje.org/urm_main.html), which require
that all authors submit signed statements of their participation in
authorship and full disclosure of any conflicts of interest. In order
to prevent the bloating of journals with pages of ‘‘recycled’’ text,
medical journals should consider using antiplagiarism software.
Supporting Information
Text S1 Articles assessed.
Found at: doi:10.1371/journal.pmed.1000425.s001 (0.09 MB
PDF)
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Background. Over the past three decades, menopausal
hormones have been heavily promoted for preventing
disease in women. However, the Women’s Health Initiative
(WHI) study—which enrolled more than 26,000 women in
the US and which was published in 2004—found that
estrogen-progestin and estrogen-only formulations (often
prescribed to women around the age of menopause)
increased the risk of stroke, deep vein thrombosis, demen-
tia, and incontinence. Furthermore, this study found that the
estrogen-progestin therapy increased rates of breast cancer.
In fact, the estrogen-progestin arm of the WHI study was
stopped in 2002 due to harmful findings, and the estrogen-
only arm was stopped in 2004, also because of harmful
findings. In addition, the study also found that neither
therapy reduced cardiovascular risk or markedly benefited
health-related quality of life measures.
Despite these results, two years after the results of WHI study
were published, a survey of over 700 practicing gynecolo-
gists—the specialists who prescribe the majority of meno-
pausal hormone therapies—in the US found that almost half
did not find the findings of the WHI study convincing and
that 48% disagreed with the decision to stop the trial early.
Furthermore, follow-up surveys found similar results.
Why Was This Study Done? It is unclear why gynecolo-
gists and other physicians continue to prescribe menopausal
hormone therapies despite the results of the WHI. Some
academics argue that published industry-funded reviews and
commentaries may be designed to convey specific, but
subtle, marketing messages and several academic analyses
have used internal industry documents disclosed in litigation
cases. So this study was conducted to investigate whether
hormone therapy–promoting tone could be identified in
narrative review articles and if so, whether these articles were
more likely to have been authored by people who had
accepted funding from hormone manufacturers.
What Did the Researchers Do and Find? The researchers
conducted a comprehensive literature search that identified
340 relevant articles published between July 2002 and June
2006—the four years following the cessation of the
estrogen-progestin arm of the women’s health initiative
study. Ten authors had published four to six articles, 47
authored two or three articles, and 371 authored one article
each. The researchers focused on authors who had published
four or more articles in the four-year period under study and,
after author names and affiliations were removed, 50 articles
were evaluated by three readers for scientific accuracy and
for tone. After individually analyzing a batch of articles, the
readers met to provide their initial assessments, to discuss
them, and to reach consensus on tone and scientific
accuracy. Then after the papers were evaluated, each
author was identified and the researchers searched for
authors’ potential financial conflicts of interest, defined as
publicly disclosed information that the authors had received
payment for research, speaking, or consulting on behalf of a
manufacturer of menopausal hormone therapy.
Common themes in the 50 articles included arguments that
clinical trial results should not guide treatment for individ-
uals and suggestions that the risks associated with hormone
therapy have been exaggerated and that the benefits of
hormone therapy have been or will be proven. Furthermore,
of the ten authors studied, eight were found to have
received payment for research, speaking or consulting on
behalf of menopause hormone manufacturers, and 30 of 32
articles evaluated as promoting hormone therapy were
authored by those with potential financial conflicts of
interest. Articles promoting the use of menopausal hormone
therapy were more than twice as likely to have been written
by authors with conflicts of interest as by authors without
conflicts of interest. Furthermore, Three authors who were
identified as having financial conflicts of interest were
authors on articles where sections of their previously
published articles were repeated word-for-word without
citation.
What Do These Findings Mean? The findings of this
study suggest that there may be a link between receiving
industry funding for speaking, consulting, or research and
the publication of apparently promotional opinion pieces on
menopausal hormone therapy. Furthermore, such publica-
tions may encourage physicians to continue prescribing
these therapies to women of menopausal age. Therefore,
physicians and other health care providers should interpret
the content of review articles with caution. In addition,
medical journals should follow the International Committee
of Medical Journal Editors Uniform Requirements for Manu-
scripts, which require that all authors submit signed state-
ments of their participation in authorship and full disclosure
of any conflicts of interest.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000425.
N The US National Heart, Lung, and Blood Institute has more
information on the Women’s Health Initiative
N The US National Institutes of Health provide more
information about the effects of menopausal hormone
replacement therapy
N The Office of Women’s Health, U.S. Department of Health
and Human Services provides information on menopausal
hormone therapy
N The International Committee of Medical Journal Editors
Uniform Requirements for Manuscripts presents Uniform
Requirements for Manuscripts published in biomedical
journals
N The National Women’s Health Network, a consumer
advocacy group that takes no industry money, has
factsheets and articles about menopausal hormone
therapy
N PharmedOut, a Georgetown University Medical Center
project, has many resources on pharmaceutical marketing
practices
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